Summary:

- The article reports on a Cleveland Clinic-led clinical trial that found a novel drug can reduce lipoprotein(a), an important risk factor for heart disease, by more than 80%.
- Lipoprotein(a) is a genetic risk factor for cardiovascular disease that is not well addressed by current therapies, so this new drug represents a significant potential advancement in heart disease prevention and treatment.
- The trial results showed the drug was well-tolerated and effective at lowering lipoprotein(a) levels, which could have important implications for reducing the risk of heart attacks, strokes, and other cardiovascular events.